• In Vitro Drug Response Metrics: Insights for Cancer Research

  2026-04-29

  Schwartz's dissertation redefines how in vitro cancer drug responses are quantified, distinguishing between relative and fractional viability to better capture the interplay of proliferative arrest and cell death. This nuanced approach offers improved assay design and interpretation, with implications for evaluating targeted agents such as tyrosine kinase inhibitors.

• Foretinib (GSK1363089): Optimizing Tumor Cell Assays in Canc

  2026-04-29

  Foretinib (GSK1363089) stands out as a robust ATP-competitive multikinase inhibitor for dissecting tumor growth, cell motility, and metastasis in translational cancer models. This guide consolidates evidence-based workflows, troubleshooting insights, and best practices to maximize reproducibility and impact in preclinical oncology research.

• Reelin Signaling as a Determinant of Ketamine Antidepressant

  2026-04-28

  This study demonstrates that intact synaptic Reelin signaling is essential for ketamine's antidepressant and synaptic effects in the hippocampus. Disruption of the Reelin-Apoer2-SFK pathway impairs both behavioral and neurophysiological responses to ketamine, providing mechanistic insight into nonresponsiveness in treatment-resistant depression.

• Red Blood Cell Lysis Buffer: Mechanistic Insights for Transl

  2026-04-28

  Unlock the full potential of blood sample preparation with evidence-driven guidance on ammonium chloride-based erythrocyte lysis. This article bridges mechanistic understanding with strategic workflow integration, enabling translational researchers to achieve reproducible, high-quality results in hematology and immunology. We position APExBIO’s Red Blood Cell Lysis Buffer as the gold standard, drawing from recent molecular research and comparative analyses.

• Precision Use of Pazopanib (GW-786034) in Advanced Cancer Mo

  2026-04-27

  Explore how Pazopanib (GW-786034) redefines precision cancer research through advanced mechanistic insights, context-driven protocol optimization, and data-backed application in ATRX-deficient tumor models. This article uniquely bridges molecular pharmacology with practical assay decisions.

• Sunitinib: Multi-Targeted RTK Inhibitor in Renal Cell Carcin

  2026-04-27

  Sunitinib empowers cancer researchers with precise, multi-pathway RTK inhibition and robust anti-angiogenic effects, now further enhanced by innovative combination strategies. Explore actionable workflows, protocol optimizations, and cutting-edge applications in renal cell carcinoma and beyond.

• Salinomycin as a Polyether Ionophore: Mechanistic Insights f

  2026-04-26

  Explore the mechanistic depth of Salinomycin, a polyether ionophore antibiotic, in hepatocellular carcinoma research. This article uniquely integrates molecular transport mechanisms, cytotoxicity considerations, and advanced protocol guidance for maximizing experimental rigor.

• Resiniferatoxin (RTX): Transforming Analgesia Research in OA

  2026-04-25

  Resiniferatoxin (RTX) stands out as a selective and ultra-potent TRPV1 agonist, delivering unprecedented nerve desensitization and durable pain relief in preclinical and clinical models of osteoarthritis. With precise dosing and robust safety profiles, RTX unlocks advanced workflows for dissecting pain pathways and developing next-generation analgesic agents.

• BH3 Mimetics Target Senescent Cells in TP53 Wild-Type Breast

  2026-04-24

  This study demonstrates that BH3 mimetics, specifically BCL-XL inhibitors, selectively eliminate chemotherapy-induced senescent breast cancer cells in TP53 wild-type settings. The findings highlight a strategy to minimize residual disease and improve outcomes in patient populations that typically show poor chemotherapy responses.

• GPR107 Deficiency Drives Diabetic Nephropathy via AT1R/Ca2+

  2026-04-24

  Xu et al. (2025) reveal that loss of GPR107 in podocytes intensifies diabetic nephropathy by disrupting clathrin-mediated endocytosis of AT1R, thus aberrantly activating calcium signaling and promoting collagen IV accumulation. These results clarify a mechanistic link between impaired endocytosis, Ca2+ signaling, and glomerular damage, suggesting GPR107 as a potential therapeutic target for kidney complications in diabetes.

• SU 5402: Applied Workflows for Cancer Biology & Neuronal Mod

  2026-04-23

  SU 5402 stands out as a versatile inhibitor for dissecting receptor tyrosine kinase signaling in both cancer and neuronal research. This article details experimental workflows, protocol optimizations, and troubleshooting tips that maximize the compound’s value, with insights drawn from validated human iPSC-neuron and oncology models.

• WZ4003: Applied Uses of a Potent NUAK1/2 Inhibitor in Cell a

  2026-04-23

  WZ4003 unlocks precision control over NUAK1/2 signaling, enabling researchers to dissect cell migration, proliferation, and tau phosphorylation with high specificity. This guide covers detailed workflows, assay enhancements, and troubleshooting strategies that maximize reproducibility and insight using APExBIO’s WZ4003.

• Methyl-β-cyclodextrin: Practical Guide for Cholesterol Extra

  2026-04-22

  Methyl-β-cyclodextrin is a high-purity reagent for selective cholesterol and lipid extraction from cell membranes, supporting studies in membrane fluidity and lipid raft dynamics. It is intended for controlled research use and not for diagnostic or medical applications, with strict recommendations on solution freshness and storage. Researchers should follow specified protocol and QC parameters to maximize reproducibility and avoid common pitfalls.

• Advancing In Vitro Drug Response Metrics in Cancer Research

  2026-04-22

  Schwartz's dissertation introduces an innovative framework for distinguishing between proliferative arrest and cell death in cancer drug studies, revealing that most agents—including topoisomerase 1 inhibitors—impact both parameters with distinct kinetics. These insights refine assay interpretation and support more accurate evaluation of antitumor agents in preclinical research.

• DiD (DiDC 18 (5)) for High-Fidelity Plasma Membrane Staining

  2026-04-21

  DiD (DiDC 18 (5)) delivers uniform, robust plasma membrane labeling, ideal for tracking cell migration and neuronal pathways—even in autofluorescent or inflammatory microenvironments. This guide translates recent innovations and practical workflows into actionable protocols, troubleshooting, and advanced use-cases for next-generation cell biology.

15469 records 1/1032 page Next 12345 下5页 Last page